Dr. Carey on Tailoring Treatment in Triple-Negative Breast Cancer

Lisa A. Carey, MD
Published Online: Monday, Mar 20, 2017



Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment for patients with triple-negative breast cancer (TNBC).

Currently, platnium-based treatments are being explored, but they are still a work in progress, says Carey. Studies are showing promise, but there is a lack of information to prove that their success translates into overall survival for patients.

The future of tailoring treatment, says Carey, is based on the effectiveness of biomarker development—including immune biomarkers. Also, non-cytotoxic options need to be included in the treatment landscape, as there are none currently available.
 


Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment for patients with triple-negative breast cancer (TNBC).

Currently, platnium-based treatments are being explored, but they are still a work in progress, says Carey. Studies are showing promise, but there is a lack of information to prove that their success translates into overall survival for patients.

The future of tailoring treatment, says Carey, is based on the effectiveness of biomarker development—including immune biomarkers. Also, non-cytotoxic options need to be included in the treatment landscape, as there are none currently available.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections: 15th Annual International Congress on the Future of Breast Cancer®Oct 06, 20172.0
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
Publication Bottom Border
Border Publication